Dr. Eric Mullins, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
At a glance
- Medical school
- University of Missouri, Columbia School of Medicine (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: University of Missouri, Columbia School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
OH license 35090164
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Children's Hospital Medical Center (711 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 2 companies reported 6 payments worth $10,425 in total to this clinician.
| Novo Nordisk Inc | $10,276 |
|---|---|
| Genentech USA, Inc. | $149 |
| Consulting Fee | $9,334 |
|---|---|
| Travel and Lodging | $725 |
| Food and Beverage | $366 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Dec 3, 2025 | Consulting Fee | $9,334 |
| Novo Nordisk Inc Dec 3, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $265 |
| Novo Nordisk Inc Dec 3, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $263 |
| Novo Nordisk Inc Dec 3, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $197 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $16,353 in research payments for these studies, mostly to the institutions running them.
- A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT02615691 - A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT03879135
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.